{
    "xml": "<topic id=\"PHP33877\" outputclass=\"drug\" rev=\"1.12\" type=\"drug\" namespace=\"/drugs/vismodegib\" basename=\"vismodegib\" title=\"VISMODEGIB\">\n<title>VISMODEGIB</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1269\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/vismodegib\">Vismodegib</xref>\n</p>\n<data name=\"vtmid\">703813003</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_681463391\" title=\"Hedgehog pathway inhibitors\">Hedgehog pathway inhibitors</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP68523\" outputclass=\"drugAction\" rev=\"1.8\" parent=\"/drugs/vismodegib\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>Vismodegib is a hedgehog pathway inhibitor.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP68495\" outputclass=\"indicationsAndDose\" rev=\"1.13\" parent=\"/drugs/vismodegib\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Symptomatic metastatic basal cell carcinoma</p>\n<p outputclass=\"therapeuticIndication\">Locally advanced basal cell carcinoma not appropriate for surgery or radiotherapy</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>150&#8239;mg once daily.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP68540\" outputclass=\"importantSafetyInformation\" rev=\"1.9\" parent=\"/drugs/vismodegib\">\n<title>Important safety information</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"title\">Risks of incorrect dosing of oral anti-cancer medicines</p>\n<p>The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy. Standards to be followed to achieve this include:</p>\n<ul>\n<li>non-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity</li>\n<li>staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital</li>\n</ul>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP68368\" outputclass=\"interactions\" rev=\"1.8\" parent=\"/drugs/vismodegib\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (vismodegib).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP68329\" outputclass=\"sideEffects\" rev=\"1.8\" parent=\"/drugs/vismodegib\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Abdominal pain</ph>; <ph outputclass=\"sideEffect\">abnormal hair growth</ph>; <ph outputclass=\"sideEffect\">alopecia</ph>; <ph outputclass=\"sideEffect\">amenorrhoea</ph>; <ph outputclass=\"sideEffect\">arthralgia</ph>; <ph outputclass=\"sideEffect\">constipation</ph>; <ph outputclass=\"sideEffect\">decreased appetite</ph>; <ph outputclass=\"sideEffect\">dehydration</ph>; <ph outputclass=\"sideEffect\">diarrhoea</ph>; <ph outputclass=\"sideEffect\">dyspepsia</ph>; <ph outputclass=\"sideEffect\">hyponatraemia</ph>; <ph outputclass=\"sideEffect\">malaise</ph>; <ph outputclass=\"sideEffect\">muscle spasms</ph>; <ph outputclass=\"sideEffect\">musculoskeletal pain</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">pruritus</ph>; <ph outputclass=\"sideEffect\">rash</ph>; <ph outputclass=\"sideEffect\">taste disturbances</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>; <ph outputclass=\"sideEffect\">weight loss</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP68562\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/vismodegib\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>For women of child-bearing potential, pregnancy must be excluded before initiation of treatment, and monthly during treatment.</p>\n<p>Women must use two contraceptive methods (including one highly effective method and one barrier method) during treatment and for 24 months after the final dose of vismodegib.</p>\n<p>Men must use a condom during treatment and for 2 months after the final dose.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP68360\" outputclass=\"pregnancy\" parent=\"/drugs/vismodegib\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>\n<b>Important: teratogenic risk</b>&#8212;may cause severe birth defects and embryo-foetal death.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP68586\" outputclass=\"breastFeeding\" parent=\"/drugs/vismodegib\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid during treatment and for 24 months after final dose.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP68511\" outputclass=\"hepaticImpairment\" parent=\"/drugs/vismodegib\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>No information available&#8212;manufacturer advises caution in moderate to severe impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP68351\" outputclass=\"renalImpairment\" parent=\"/drugs/vismodegib\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>No information available&#8212;manufacturer advises caution in severe impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP58092\" outputclass=\"prescribingAndDispensingInformation\" rev=\"1.9\" parent=\"/drugs/vismodegib\">\n<title>Prescribing and dispensing information</title>\n<body>\n<section>\n<sectiondiv>\n<p>Prescribers and pharmacists must comply with prescribing and dispensing restrictions as specified in the manufacturer&#8217;s Pregnancy Prevention Programme, and ensure that the patient fully acknowledges the programme&#8217;s pregnancy prevention measures&#8212;consult product literature for further information.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP68354\" outputclass=\"patientAndCarerAdvice\" rev=\"1.22\" parent=\"/drugs/vismodegib\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"patientAdviceInConceptionAndContraception\">\n<title>Patient advice required around conception and contraception</title>\n<sectiondiv>\n<p>Counselling on pregnancy and contraception advised. Patients must comply with the manufacturer&#8217;s pregnancy prevention programme.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP33877-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/vismodegib\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75429\" title=\"Capsule\" namespace=\"/drugs/vismodegib/capsule\">Capsule</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1269\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/vismodegib\" title=\"Vismodegib\" count=\"1\" rel=\"link\">Vismodegib</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75429\" namespace=\"/drugs/vismodegib/capsule\" title=\"Capsule\" count=\"1\" rel=\"link\">Capsule</xref>\n</links>\n</topic>",
    "id": "PHP33877",
    "outputclass": "drug",
    "rev": "1.12",
    "type": "drug",
    "namespace": "/drugs/vismodegib",
    "basename": "vismodegib",
    "title": "VISMODEGIB",
    "interactants": [
        {
            "id": "bnf_int_1269",
            "label": "Vismodegib"
        }
    ],
    "vtmid": "703813003",
    "drugClassification": [
        "Hedgehog pathway inhibitors"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Vismodegib is a hedgehog pathway inhibitor.",
                "html": "<p>Vismodegib is a hedgehog pathway inhibitor.</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Symptomatic metastatic basal cell carcinoma",
                        "html": "Symptomatic metastatic basal cell carcinoma"
                    },
                    {
                        "textContent": "Locally advanced basal cell carcinoma not appropriate for surgery or radiotherapy",
                        "html": "Locally advanced basal cell carcinoma not appropriate for surgery or radiotherapy"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "150 mg once daily.",
                        "html": "<p>150&#8239;mg once daily.</p>"
                    }
                ]
            }
        ]
    },
    "importantSafetyInformation": {
        "importantSafetyInformation": [
            {
                "type": "importantSafetyInformation",
                "title": "Risks of incorrect dosing of oral anti-cancer medicines",
                "textContent": "The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy. Standards to be followed to achieve this include:\n\nnon-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital",
                "html": "<p>The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy. Standards to be followed to achieve this include:</p><ul>\n<li>non-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity</li>\n<li>staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital</li>\n</ul>"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (vismodegib).",
                "html": "<p>Appendix 1 (vismodegib).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Abdominal pain",
                        "html": "Abdominal pain",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "abnormal hair growth",
                        "html": "abnormal hair growth",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "alopecia",
                        "html": "alopecia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "amenorrhoea",
                        "html": "amenorrhoea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "arthralgia",
                        "html": "arthralgia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "constipation",
                        "html": "constipation",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "decreased appetite",
                        "html": "decreased appetite",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dehydration",
                        "html": "dehydration",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "diarrhoea",
                        "html": "diarrhoea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dyspepsia",
                        "html": "dyspepsia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hyponatraemia",
                        "html": "hyponatraemia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "malaise",
                        "html": "malaise",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "muscle spasms",
                        "html": "muscle spasms",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "musculoskeletal pain",
                        "html": "musculoskeletal pain",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "pruritus",
                        "html": "pruritus",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "taste disturbances",
                        "html": "taste disturbances",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "weight loss",
                        "html": "weight loss",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ]
            }
        }
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "For women of child-bearing potential, pregnancy must be excluded before initiation of treatment, and monthly during treatment.\n\nWomen must use two contraceptive methods (including one highly effective method and one barrier method) during treatment and for 24 months after the final dose of vismodegib.\n\nMen must use a condom during treatment and for 2 months after the final dose.",
                "html": "<p>For women of child-bearing potential, pregnancy must be excluded before initiation of treatment, and monthly during treatment.</p><p>Women must use two contraceptive methods (including one highly effective method and one barrier method) during treatment and for 24 months after the final dose of vismodegib.</p><p>Men must use a condom during treatment and for 2 months after the final dose.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Important: teratogenic risk&#8212;may cause severe birth defects and embryo-foetal death.",
                "html": "<p>\n<b>Important: teratogenic risk</b>&#8212;may cause severe birth defects and embryo-foetal death.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid during treatment and for 24 months after final dose.",
                "html": "<p>Avoid during treatment and for 24 months after final dose.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "No information available&#8212;manufacturer advises caution in moderate to severe impairment.",
                "html": "<p>No information available&#8212;manufacturer advises caution in moderate to severe impairment.</p>"
            }
        ]
    },
    "renalImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "No information available&#8212;manufacturer advises caution in severe impairment.",
                "html": "<p>No information available&#8212;manufacturer advises caution in severe impairment.</p>"
            }
        ]
    },
    "prescribingAndDispensingInformation": {
        "prescribingAndDispensingInformation": [
            {
                "type": "prescribingAndDispensingInformation",
                "textContent": "Prescribers and pharmacists must comply with prescribing and dispensing restrictions as specified in the manufacturer&#8217;s Pregnancy Prevention Programme, and ensure that the patient fully acknowledges the programme&#8217;s pregnancy prevention measures&#8212;consult product literature for further information.",
                "html": "<p>Prescribers and pharmacists must comply with prescribing and dispensing restrictions as specified in the manufacturer&#8217;s Pregnancy Prevention Programme, and ensure that the patient fully acknowledges the programme&#8217;s pregnancy prevention measures&#8212;consult product literature for further information.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "patientAdviceInConceptionAndContraception": [
            {
                "type": "patientAdviceInConceptionAndContraception",
                "textContent": "Counselling on pregnancy and contraception advised. Patients must comply with the manufacturer&#8217;s pregnancy prevention programme.",
                "html": "<p>Counselling on pregnancy and contraception advised. Patients must comply with the manufacturer&#8217;s pregnancy prevention programme.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP75429",
                "label": "Capsule",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1269",
                "label": "Vismodegib",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP75429",
                "label": "Capsule",
                "type": "medicinalForm"
            }
        ]
    }
}